Radioligand therapy transforms cancer care by targeting neuroendocrine tumors and prostate cancer, indicating a shift to precision medicine.
Radioligand therapy (RLT) is a recent term for long established nuclear medicine practices. Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include ⁶⁸Ga-DOTATATE and ¹⁷⁷Lu-DOTATATE, which target somatostatin receptor subtype 2 in neuroendocrine tumors, and ⁶⁸Ga-PSMA-617 and ¹⁷⁷Lu-PSMA-617, which target prostate cancer. There are several challenges and opportunities in the realization of precision medicine through RLT. RLT, weaponized in cancer management through advances in instrumentation and radiochemistry, is transforming the nuclear oncology landscape. Equitable access to these advanced tools remains a global consideration.
No takes yet. Share an insight, caveat, or question.
Currie et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: